



Advances in Nanomaterial-Based Drug Delivery Systems

Guest Editor:

Dr. Donghui Song

Department of Biomedical
Engineering, Tufts University,
Medford, MA 02155, USA

Deadline for manuscript
submissions:

closed (31 May 2024)

Message from the Guest Editor

Dear colleagues,

I would like to invite you to contribute new discoveries that may help advance the applications of nanotechnology in drug delivery.

Nanotechnology has been utilized in clinics. Despite remarkable progress in the past few decades, challenges are still associated with nanomedicine. Biological barriers limit nanoparticles' delivery of therapeutic drugs to the desired tissues or cells. The low efficiency of clinical translation indicates that there are safety and regulation issues. This Special Issue aims to publish up-to-date progress in engineering novel nanomaterials and formulations for delivering small-molecule and biologic drugs, strategies of enhancing the therapeutic outcome in treating diseases, such as cancer and autoimmune and infectious diseases, and mechanisms of improving the delivery efficiency of nanoparticles. I hope the contributions to this Special Issue will cast some light on improving the therapeutic effect and reducing the side effects of nanoparticle-based drug delivery systems in cancer therapy, gene therapy, and immunotherapy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI